LAUSR

Adenosine deaminase acting on RNA (ADAR) catalyzes the posttranscriptional conversion of adenosine to inosine in double‐stranded RNA (dsRNA), which can lead to the creation of missense mutations in coding sequences. Recent studies show that editing‐dependent functions of ADAR1 protect dsRNA from dsRNA‐sensing molecules and inhibit innate immunity and the interferon‐mediated response. Deficiency in these ADAR1 functions underlie the pathogenesis of autoinflammatory diseases such as the type I interferonopathies Aicardi‐Goutieres syndrome and dyschromatosis symmetrica hereditaria. ADAR1‐mediated editing of endogenous coding and noncoding RNA as well as ADAR1 editing‐independent interactions with DICER can also have oncogenic or tumor suppressive effects that affect tumor proliferation, invasion, and response to immunotherapy. The combination of proviral and antiviral roles played by ADAR1 in repressing the interferon response and editing viral RNAs alters viral morphogenesis and cell susceptibility to infection. This review analyzes the structure and function of ADAR1 with a focus on its position in human disease pathways and the mechanisms of its disease‐associated effects.